BioSpace News Archive

According to Nova one advisor, the global Generic Pharmaceuticals Contract Manufacturing market was valued at USD 63.18 billion in 2021 and it is expected to hit around USD 107.9 billion by 2030 with a CAGR of 5.17% during the forecast period 2022 to 2030.

BioT Medical, a company providing a validated cloud-native platform for building new care models based on Internet of Medical Things (IoMT) medical devices - in a day instead of years, announced a strategic agreement with NTT DATA, a digital business and IT services leader.

Motus GI Holdings, Inc. reported its financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease, reported financial results for the third quarter of 2022 and provided a business update.

Mednovation is very pleased to announce that it has entered into a cooperation agreement with Life Science Intelligence, Inc. to promote the parties to the Medtech industry worldwide, and to cooperate with each other to support development and innovation in the Chinese Medtech market.

Indivior PLC and Opiant Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which Indivior will acquire Opiant for an upfront consideration of $20.00 per share, in cash, plus up to $8.00 per share in contingent value rights that may become payable in the event that certain net revenue milestones are achieved during the relevant seven-year period by OPNT003 after its approval and launch.

Sentinel CH. SpA announced the launch of SENTiNAT® 200, the fully automated sample to result system, and STAT-NAT® SN200 Real-Time PCR assays for the quantitative detection of 10 viruses.

LumiraDx Limited, a next-generation point of care diagnostics company, announced the continued commercial expansion of its HbA1c test, for professional use across multiple care settings.

Apollo Therapeutics, a portfolio biopharmaceutical company focusing on translational biology and drug development, and The Institute of Cancer Research, London, a world-leading cancer research organisation, announce they have entered into a strategic collaboration to discover and develop new cancer medicines.

Lumos Pharma, Inc., announced that interim results met expectations for its Phase 2 OraGrowtH210 Trial and Phase 2 Pharmacokinetic/Pharmacodynamic OraGrowtH212 Trial evaluating oral LUM-201 for subjects with moderate pediatric growth hormone deficiency who screened PEM-positive utilizing Lumos’s predictive enrichment marker strategy.